Beau R. Webber

3.5k total citations · 1 hit paper
55 papers, 1.9k citations indexed

About

Beau R. Webber is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Beau R. Webber has authored 55 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 24 papers in Oncology and 13 papers in Immunology. Recurrent topics in Beau R. Webber's work include CRISPR and Genetic Engineering (25 papers), CAR-T cell therapy research (23 papers) and Immune Cell Function and Interaction (12 papers). Beau R. Webber is often cited by papers focused on CRISPR and Genetic Engineering (25 papers), CAR-T cell therapy research (23 papers) and Immune Cell Function and Interaction (12 papers). Beau R. Webber collaborates with scholars based in United States, Germany and Canada. Beau R. Webber's co-authors include Branden S. Moriarity, Walker S. Lahr, Mitchell G. Kluesner, Jakub Tolar, Mark J. Osborn, Amber McElroy, Juan E. Abrahante, John Garbe, Derek Nedveck and Bruce R. Blazar and has published in prestigious journals such as Nature Communications, Blood and The Journal of Immunology.

In The Last Decade

Beau R. Webber

50 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EditR: A Method to Quantify Base Editing from Sanger Sequencing

2018 314 citations Mitchell G. Kluesner, Walker S. Lahr et al. The CRISPR Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beau R. Webber United States	20	1.4k	526	459	296	234	55	1.9k
Brian S. Garrison United States	14	1.3k 1.0×	248 0.5×	403 0.9×	341 1.2×	183 0.8×	20	1.8k
Paula Rı́o Spain	25	1.5k 1.1×	449 0.9×	532 1.2×	320 1.1×	120 0.5×	68	2.0k
Fabienne Cocchiarella Italy	15	977 0.7×	545 1.0×	386 0.8×	329 1.1×	158 0.7×	17	1.6k
Geulah Livshits United States	13	877 0.6×	433 0.8×	186 0.4×	425 1.4×	141 0.6×	18	1.5k
Michael Naso United States	14	1.1k 0.8×	290 0.6×	556 1.2×	313 1.1×	285 1.2×	28	1.8k
Megan Riddle United States	19	739 0.5×	320 0.6×	302 0.7×	361 1.2×	617 2.6×	43	1.7k
Bian Hu China	17	1.1k 0.8×	389 0.7×	360 0.8×	196 0.7×	53 0.2×	30	1.5k
Uimook Choi United States	22	1.1k 0.8×	523 1.0×	644 1.4×	478 1.6×	52 0.2×	44	1.7k
Ivo J. Huijbers Netherlands	24	954 0.7×	595 1.1×	205 0.4×	315 1.1×	162 0.7×	43	1.6k
Andreas Reik United States	20	2.5k 1.9×	706 1.3×	794 1.7×	336 1.1×	55 0.2×	47	3.2k

Countries citing papers authored by Beau R. Webber

Since Specialization

Citations

This map shows the geographic impact of Beau R. Webber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beau R. Webber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beau R. Webber more than expected).

Fields of papers citing papers by Beau R. Webber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beau R. Webber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beau R. Webber. The network helps show where Beau R. Webber may publish in the future.

Co-authorship network of co-authors of Beau R. Webber

This figure shows the co-authorship network connecting the top 25 collaborators of Beau R. Webber. A scholar is included among the top collaborators of Beau R. Webber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beau R. Webber. Beau R. Webber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heltemes-Harris, Lynn, Todd P. Knutson, Yinjie Qiu, et al.. (2025). Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells. Blood. 146(23). 2779–2793.

Kluesner, Mitchell G., Emily J. Pomeroy, Joseph G. Skeate, et al.. (2025). Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing. Journal for ImmunoTherapy of Cancer. 13(5). e009560–e009560. 8 indexed citations

Folsom, Timothy D., et al.. (2025). Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks. Frontiers in Immunology. 16. 1704404–1704404.

Laoharawee, Kanut, et al.. (2024). Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders. Molecular Therapy. 32(11). 3865–3878.

Menegatti, Silvia, Sheila López‐Cobo, Sandrine Heurtebise-Chrétien, et al.. (2024). Ablation of FAS confers allogeneic CD3– CAR T cells with resistance to rejection by T cells and natural killer cells. Nature Biomedical Engineering. 8(12). 1651–1664. 7 indexed citations

Sangala, Jules, Philippa R Kennedy, Emily J. Pomeroy, et al.. (2023). Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine Production. The Journal of Immunology. 210(8). 1108–1122. 6 indexed citations

Lahr, Walker S., et al.. (2023). CRISPR-Cas9 base editors and their current role in human therapeutics. Cytotherapy. 25(3). 270–276. 11 indexed citations

Spartz, Ellen J., Walker S. Lahr, Yun You, et al.. (2023). Germline T cell receptor exchange results in physiological T cell development and function. Nature Communications. 14(1). 528–528. 2 indexed citations

Kluesner, Mitchell G., Tomoyuki Koga, Miller Huang, et al.. (2022). Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies. The CRISPR Journal. 5(4). 517–535. 3 indexed citations

10.

Tabdanov, Erdem D., Alexander X. Cartagena‐Rivera, Emily J. Pomeroy, et al.. (2021). Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments. Nature Communications. 12(1). 2815–2815. 90 indexed citations

11.

Kluesner, Mitchell G., Walker S. Lahr, Cara-lin Lonetree, et al.. (2021). CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nature Communications. 12(1). 2437–2437. 74 indexed citations

12.

Osborn, Mark J., Gregory A. Newby, Amber McElroy, et al.. (2019). Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. Journal of Investigative Dermatology. 140(2). 338–347.e5. 75 indexed citations

13.

Pomeroy, Emily J., John Hunzeker, Mitchell G. Kluesner, et al.. (2019). A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy. 28(1). 52–63. 139 indexed citations

14.

Johnson, Matthew J., Kanut Laoharawee, Walker S. Lahr, Beau R. Webber, & Branden S. Moriarity. (2018). Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. Scientific Reports. 8(1). 12144–12144. 62 indexed citations

15.

Matson, Jacob P., ‎Raluca Dumitru, Philip Coryell, et al.. (2017). Rapid DNA replication origin licensing protects stem cell pluripotency. eLife. 6. 64 indexed citations

16.

Webber, Beau R., Ron McElmurry, Cindy Eide, et al.. (2017). Rapid generation of Col7a1−/− mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Laboratory Investigation. 97(10). 1218–1224. 29 indexed citations

17.

Osborn, Mark J., Cara-lin Lonetree, Beau R. Webber, et al.. (2016). CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. Stem Cells and Development. 25(20). 1591–1603. 26 indexed citations

18.

Webber, Beau R. & Jakub Tolar. (2015). From Marrow to Matrix: Novel Gene and Cell Therapies for Epidermolysis Bullosa. Molecular Therapy. 23(6). 987–992. 9 indexed citations

19.

Osborn, Mark J., Richard Gabriel, Beau R. Webber, et al.. (2014). Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. Human Gene Therapy. 26(2). 114–126. 91 indexed citations

20.

Webber, Beau R., Michelina Iacovino, Si Ho Choi, et al.. (2013). DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo. Blood. 122(17). 2978–2986. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact